Literature DB >> 8626867

The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.

M J Castillo1, A J Scheen, P J Lefèbvre.   

Abstract

This study aims at investigating the influence of the prevailing blood glucose level on the metabolic deterioration that follows a nocturnal interruption of a continuous sc insulin infusion (CSII). Fifteen CSII-treated, C-peptide negative, diabetic patients have been studied CSII was interrupted from 2300 h to 0500 h. Blood was collected hourly from 2200 h to 0600 h. According to blood glucose (BG) levels at 2300 h, patients were classified as hypoglycemic (BG between 1.5 and 2.5 mmol/L, n = 5), normoglycemic (BG between 4.0 and 8.0 mmol/L, n = 5), or hyperglycemic (BG between 9.0 and 15.0 mmol/L, n = 5). At 2300 h, BG (mean +/- SEM) was 1.9 +/- 0.1, 6.2 +/- 0.7 and 11.2 +/- 1.0 mmol/L, respectively. After 6 h of CSII interruption, BG increased to 13.5 +/- 1.3, 14.1 +/- 1.2, and 19.4 +/- 1.2 mmol/L, respectively. At 2300 h, plasma 3-OH-butyrate levels were similar in the three groups (around 150 micromol/L). At 0500 h, significantly higher values were obtained for hyperglycemic (1460 +/- 127 micromol/L) than for normoglycemic (868 +/- 150 micromol/L) or hypoglycemic (837 +/- 80 micromol/L) patients. Enhanced lipolysis in initially hyperglycemic patients may contribute to accelerated ketogenesis and metabolic degradation. In conclusion, the metabolic deterioration that follows CSII interruption is influenced by the initial metabolic situation. Hypoglycemic patients deteriorate more rapidly, and hyperglycemic patients suffer a more important degradation. The latter are prone to rapid ketoacidosis if accidental CSII interruption occurs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626867     DOI: 10.1210/jcem.81.5.8626867

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Innovations in technology for the treatment of diabetes: clinical development of the artificial pancreas (an autonomous system).

Authors:  David C Klonoff; Charles L Zimliki; Lcdr Alan Stevens; Patricia Beaston; Arleen Pinkos; Sally Y Choe; Guillermo Arreaza-Rubín; William Heetderks
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

2.  Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspension.

Authors:  R Paul Wadwa; H Peter Chase; Dan Raghinaru; Bruce A Buckingham; Irene Hramiak; David M Maahs; Laurel Messer; Trang Ly; Tandy Aye; Paula Clinton; Craig Kollman; Roy W Beck; John Lum
Journal:  Pediatr Diabetes       Date:  2016-07-12       Impact factor: 4.866

3.  Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension.

Authors:  Bruce Buckingham; H Peter Chase; Eyal Dassau; Erin Cobry; Paula Clinton; Victoria Gage; Kimberly Caswell; John Wilkinson; Fraser Cameron; Hyunjin Lee; B Wayne Bequette; Francis J Doyle
Journal:  Diabetes Care       Date:  2010-03-03       Impact factor: 19.112

4.  Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system.

Authors:  Roy W Beck; Dan Raghinaru; R Paul Wadwa; H Peter Chase; David M Maahs; Bruce A Buckingham
Journal:  Diabetes Care       Date:  2014       Impact factor: 19.112

5.  A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes.

Authors:  David M Maahs; Peter Calhoun; Bruce A Buckingham; H Peter Chase; Irene Hramiak; John Lum; Fraser Cameron; B Wayne Bequette; Tandy Aye; Terri Paul; Robert Slover; R Paul Wadwa; Darrell M Wilson; Craig Kollman; Roy W Beck
Journal:  Diabetes Care       Date:  2014-05-07       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.